期刊名称：NEUROSCIENCE
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
|
Neuroscience publishes papers describing the results of original research on any aspect of the scientific study of the nervous system. Any paper, however short, will be considered for publication provided that it reports significant, new and carefully confirmed findings with full experimental details. For Instructions to Authors click on "Guide to Authors" in the left-hand column. |
 | Abstracting / Indexing
- BIOSIS
- Chemical Abstracts
- Current Contents ISI/BIOMED Database
- Current Contents/ASCA
- Current Contents/Life Sciences
- Current Contents/SciSearch Database
|
- Current Contents/Science Citatation Index
- EMBASE
- Elsevier BIOBASE
- Index Medicus
- Medline
- PASCAL/CNRS
|
Instructions to Authors
I. GENERAL
II. SUBMISSION OF MANUSCRIPTS
III. PREPARATION OF MANUSCRIPTS
IV. PAPER SUBMISSION CHECKLIST
I. GENERAL
1. Neuroscience is devoted to the prompt publication of the results of original research on any aspect of the scientific study of the nervous system. The type of paper most suitable for publication is that which reports new observations that directly contribute to our understanding of how the nervous system works. The purpose and outcome of the study should be meaningful to scientists of other disciplines. Detailed and/or very specialized papers will only be considered for publication if the authors have followed the latter suggestion. The Chief and Associate Editor will seek the advice of specialists in the field and return any manuscripts they consider do not fulfil these criteria. In order to facilitate this process, consultations will not necessarily involve submitting the manuscript for full peer review. The decision of the Chief and Associate Editor is final.
2. Section Editors. With the rapid growth of neuroscience into diverse areas ranging from molecular biology to cognitive science, it is essential for the Chief and Associate Editor to have advice from neuroscientists representing all major areas of research in order to have a fair and efficient review process. Section Editors have been appointed in the areas of Behavioral Neuroscience, Cellular, Clinical, Cognitive, Developmental, Molecular, Neuropharmacology, Systems Neuroscience and Sensory Systems. Section Editors play an integral role in all facets of the review process.
3. The Editorial Board. The international Editorial Board, which is appointed by the Publications Committee of IBRO, consists of specialists in all major areas of neuroscience. Each paper is read by at least two Editors or other referees. Further opinions are sought if necessary. Papers are accepted by the Chief and Associate Editor in consultation with the appropriate Section Editor. The review and decision process will be identical regardless of whether a manuscript is submitted to the Davis or Oslo Editorial Offices. All manuscripts are subject to any modifications required by the Editorial Assistant to conform to Journal policy.
4. Types of papers
(a) Research papers reporting original research are considered for publication provided that they describe significant and substantial new findings and that adequate experimental details are given. Preliminary communications are not accepted. No distinction is made between short and long papers. There are no specific page limits although authors are encouraged to be as concise as possible and to use as few illustrations as necessary to adequately document their findings.
(b) Letters to Neuroscience. These are short communications of outstanding new discoveries of interest to a broad range of neuroscientists. They should be up to 2500 words, inclusive of all text, with no more than 30 references. All accepted Letters to Neuroscience will be first published on the Neuroscience website http//www.neuroscience-ibro.com within 15 working days of acceptance.
(c) Commentaries on a specific topic in neuroscience will normally be accepted only following an invitation to the author from the Chief or Associate Editor or from one of the Section Editors. Other prospective authors should obtain their agreement before submitting a manuscript. Commentaries are not exhaustive reviews but short articles (3000-10,000 words in length) intended to either draw attention to developments in a specific field for workers in other scientific disciplines, or to bring together observations over a wide area that seem to point in a new direction, or to give the author's personal views on a controversial topic, or to direct soundly based criticism at some widely held dogma or widely used technique in neuroscience. Authors should always endeavour to make their Commentary understandable to neuroscientists of other disciplines.
(d) Matters Arising. A limited amount of space in the Journal will be available for scientific comments about articles published in this Journal. Such comments should be sent to the Chief or Associate Editor and they should be no more that 1500 words long excluding references. They should be confined to important scientific points that arise out of papers previously published in Neuroscience. The Chief and Associate Editor reserve the right to invite replies to such comments by the authors of the original papers. They also decide when comments of this nature on any particular topic should be closed and after this point no further comments on the same original article will be published.
II. SUBMISSION OF MANUSCRIPTS
Submission of any form of paper to Neuroscience will be held to imply that it represents original research not previously published, in whole or in part (except in the form of an abstract or preliminary report) and that it is not being considered for publication elsewhere in similar form, in any language, without the consent of the Chief or Associate Editor. All papers must be prepared according to the instructions given in Section III. Each manuscript should be accompanied by a signed covering letter in which the corresponding author states: "The work described has not been submitted for publication, in whole or in part, elsewhere and all the authors listed have approved the manuscript that is enclosed". For all papers the original and four copies (i.e. five copies) of each manuscript plus an electronic version (including figures) preferably PDF should be submitted to the Neuroscience Editorial Office: 525 B Street, Suite 1900, San Diego, CA 92101-4495, USA neuroscience@journal-office.com
Editors: Dr David G. Amaral, Neuroscience Editorial Office, Department of Psychiatry TB171, University of California Davis, One Shields Avenue, Davis, CA 95616, USA, David G. Amaral NeuroscienceEditor@ucdavis.edu or Professor O.P. Ottersen, Centre for Molecular Biology and Neuroscience, Institute of Basic Medical Sciences, Department of Anatomy, Sognsvannsv 9, P O Box 1105, Blindern, NO 0317, Oslo, Norway, editor.neuroscience@basalmed.uio.no
The cover letter should indicate which of the following Section Editors is appropriate for handling of the manuscript, as well as whether Dr Amaral or Professor Ottersen should be the main handling Editor.
(a) Behavioral Neuroscience Dr Edvard I Moser, Center for the Biology of Memory, MTFS, Neuroscience Unit, Norwegian Univesity of Science and Technology, NO 7489, Trondheim, Norway
(b) Cellular. Dr Contstantino Sotelo, INSERM U-106, 47 Boulevard de l' Hopital, 75651 Paris, Cedex 13, France
(c) CellularProfessor Stephen J. Redman, Division of Neuroscience, Australian National University, John Curtin School Medical Research, Canberra ACT, Australia.
(d) Clinical. Dr David A. Lewis, Department of Psychiatry, University of Pittsburgh, W1652 BST, 3811 O Hara Street, Pittsburgh, PA 15213-2593, USA.
(e) Cognitive. Dr Raymond J. Dolan, Wellcome Department of Cognitive Neurology, Queen Square, London, WC1N 3BG, UK.
(f) Developmental. Dr John L. R. Rubenstein, LPPI Box F-0984, University of California at San Francisco, 401 Parnassus Avenue, San Francisco, CA 94143-0984, USA.
(g) Molecular. Dr Werner Sieghart, Brain Research Institute, University of Vienna, Division of Biochemistry and Molecular Biology, Spitalgasse 4, A-1090 Vienna, Austria.
(h) Neuropharmacology. Dr J. Paul Bolam, MRC Anatomical and Neuropharmacology Unit, Mansfield Road, Oxford, OX1 3TH, UK.
(i) Systems Neuroscience. Dr Gyorgy Buzsaki, Center for Molecular and Behavioural Neuroscience, Rutgers University, 197 University Avenue, Newark, NJ 07102, USA.
(j) Systems Neuroscience. Dr Keiji Tanaka, Cognitive Brain Mapping Laboratory, RIKEN Brain Science Institute, 2-21-3 Hirosawa, Wako, Saitama 351-0198, Japan
(k) Sensory Systems Dr David Fitzpatrick, Department of Neurobiology, Duke University, 427C Bryan Res. Building, Box 3209 Med. Center, Durham, NC 27710, USA
Please do not send manuscripts direct to Dr Amaral, Professor Ottersen, or the Section Editors. All submissions should instead be made to the San Diego office, as detailed above.
Submission of any manuscript must be accompanied by a completed Submissions Checklist, which can be found at the end of these instructions for authors. Submission of a manuscript without or with an incomplete checklist may result in a delay in the processing or the return of the manuscript to the authors. In order to ensure an expedient review, authors should also enclose a separate electronic file that includes the cover letter, title page, abstract and references. This will be transmitted electronically to potentially suitable referees as part of the selection procedure.
Commentaries should be submitted in quadruple (i.e. original and three copies) along with the electronic files directly to the Editorial Office.
Referees. Authors should suggest at least four suitable Referees for their manuscripts on submission, giving telephone and fax numbers, and e-mail addresses as well as postal addresses. These should be listed in the covering letter.
Cover illustrations. Authors are encouraged to submit visually and scientifically interesting figure(s) representative of their data, though not necessarily as they appear in the manuscript, for potential cover illustrations. The use of cover illustrations is dependent on the associated paper being accepted for publication, and is at the discretion of the Editors.
III. PREPARATION OF MANUSCRIPTS
1. Organization
(a) All manuscripts must be typewritten with double spacing throughout (including references, tables and figure legends) and with margins at least 2.5 cm wide. Pages should be numbered in succession, the title page being no. 1.
(b) The title page should include the title, the authors' names and affiliations, full contact details (address, telephone and fax numbers, and e-mail address) of the corresponding author, any necessary footnotes, and the appropriate Section Editor (if applicable) to whom the manuscript should be sent for handling. The title should be as short as is consistent with clarity and devoid of abbreviations. Papers should not be numbered in series, but subtitles are accepted. A comprehensive list of abbreviations used in the main text should be put on a separate page that follows the title page.
(c) A running title, not to exceed 56 character spaces, should be included on a separate sheet.
(d) Each paper must begin with a brief Abstract of approximately 300 words. The abstract should summarize the results obtained and have a final paragraph summarizing the major conclusions in such a way that a reader not familiar with the techniques used can see any implications for his or her area of neuroscience. Abbreviations must be kept to a minimum in the abstract.
(e) Authors are asked to include a maximum of six key words (not used in the title) at the foot of the abstract.
(f) Research papers should be organized in the following four main sections:
(i) Introduction. An introductory statement should first "set the scene" for a non-specialist and then continue with the specific reasons for undertaking the investigation. The heading "Introduction" should be omitted and no results should be presented.
(ii) Experimental procedures. Procedures used should be given in sufficient detail to permit the replication of the work by others. However, previously published procedures should be referenced and briefly summarized, and only described in detail if they have been substantially modified. The source of all materials, including animals and human tissue, must be provided. The location of each supplier should be detailed on first use in the text.
Experiments on humans and animals. All experiments on human subjects should be conducted in accordance with the Declaration of Helsinki http://www.wma.net. Manuscripts must include, in the Experimental procedures section, a statement that all procedures were carried out with the adequate understanding and written consent of the subjects. All animal experiments should be carried out in accordance with the UK Animals (Scientific Procedures) Act 1986 and associated guidelines, the European Communities Council Directive of 24 November 1986 (86/609/EEC) or the National Institute of Health Guide for the Care and Use of Laboratory Animals (NIH Publications No. 80-23) revized 1996. Manuscripts should include a statement when appropriate, that all efforts were made to minimize the number of animals used and their suffering. Authors are advized to consult ``A fair press for animals' [New Scientist (1992) 1816, 18-30]. The Chief and Associate Editor reserve the right to return papers if there is doubt as to whether suitable procedures have been used.
The Experimental procedures must include a section detailing all of the statistical tests applied to the data and must state the probability level at which the Null Hypothesis was rejected.
(iii) Results. In this section findings should be described without discussion of their significance. Sub-sections should be used in order to clarify the expression of the results.
(iv) Discussion. In this section the authors' interpretations of their findings should be accompanied by an assessment of their significance in relation to previous work. Repetition of material given under "Results" should be avoided. Sub-sections dealing with technical or highly specialized matter should be clearly separated from the rest of the text so that they can be printed in small type.
(g) Letters to Neuroscience: As for Research papers, except each part should be substantially smaller in word count and a minimal number of figures should be included.
(h) Commentaries should have a title page giving the title, authors' names and affiliations, contact details of the corresponding author, a comprehensive list of abbreviations used in the manuscript, and a statement of the number of words in the full text. A running title, a maximum of six keywords, an Abstract containing no abbreviations and, where necessary, a Table of Contents should all be supplied on separate sheets.
(i) Personal Communications may be used only when written authorization from the communicator is submitted with the original manuscript; they may be mentioned only in the text and in the following form: (D.G Amaral, Department of Psychiatry, University of California, personal communication)
(j) Unpublished or submitted experiments by one of the authors may be mentioned only in the text; they must not be included in the References; initials, as well as surnames, must be given for authors whose unpublished experiments are quoted: (Zs. Nagy, M. M. Esiri and A. D. Smith, unpublished observations)
(k) Acknowledgements. The names and affiliations of individuals providing comments or advice in the "Acknowledgements" will only be included if authors submit written authorization from the individuals concerned.
(l) References. The reference list should be included at the end of the main text. A paper which has been accepted for publication but which has not appeared may be cited in the reference list with the abbreviated name of the journal followed by the words "in press". The latest information on an "in press" reference will be required on acceptance. If work by authors that is submitted or in press elsewhere is referred to, then four copies of each manuscript should be enclosed. Where possible, every effort should be made to cite peer-reviewed papers in preference to abstracts.
(m) Tables and figures should be included on separate pages placed at the end of the manuscript. Their desired approximate locations should be indicated in the text. Each figure must be accompanied by an explanatory legend in a separate section entitled Figure Legends. In general, tables and figures should be constructed so that they, together with their captions and legends, will be intelligible with minimal reference to the main text or each other.
2. Style
(a) Manuscripts should be written in English in a concise and understandable style. Technical jargon, "laboratory slang' or words not defined in dictionaries should not be used. It is the responsibility of the corresponding author to ensure that the manuscript is written in a style that is grammatically correct and free of spelling or other typographical errors. Redundant words, phrases, and sentences should not be used. The Editorial Office reserves the right to revize the wording of manuscripts accepted for publication in Neuroscience.
(b) The excessive use of abbreviations in the text is strongly discouraged. In order to aid communication between scientists of different disciplines, authors should only use abbreviations sparingly and should always define the abbreviation when first used in the text by placing it in parentheses after the full term, e.g. acetylcholinesterase (AChE). The abbreviations should then be used consistently thererafter and appear at least twice in the text. All abbreviations should be defined in a comprehensive alphabetical abbreviation list at the beginning of the manuscript. No abbreviations are allowed in the article title or Abstract except those that are always undefined, i.e. ADP, AMP, ATP, CNS, DNA, DOPA, GABA, RNA, i.c.v., i.m., i.p., i.v., s.c. The use of abbreviations in the abstract is occasionally allowed if the text being abbreviated is cumbersome or frequently used. The abbreviation should be defined on first use in the abstract and on first use in the main body of the text. Abbreviations are allowed in the running title, section headings, figure captions and table headings. Certain chemical abbreviations can be left undefined but should be defined in the abbreviation list, e.g. EDTA, EGTA, HEPES, MK801. Editors reserve the right to over-rule the use of "author-defined" abbreviations, i.e. awkward and unfamiliar abbreviations and those intended to express concepts or experimental techniques.
(c) Symbols for physical units should be restricted to the Systems Internationale (S.I.) Units.
(d) Greek characters should be clearly indicated.
(e) Drug names should be the official or approved names; trade names or common names may be given in brackets where the drug is first mentioned. The manufacturer's name must be given. The doses of the drugs should be given as unit weight/unit body weight, e.g. mmol/kg or mg/kg. Concentrations should be given in terms of molarity, e.g. nM or  M, or as unit weight/unit volume solution, stating whether the weight refers to the salt or the active component of the drug. The molecular weight, inclusive of water of crystallizations, should be stated if doses are given as unit weight.
(f) Footnotes to the text should be used sparingly. Where they must be used, their locations should be indicated by the symbols *,  , , ?, || , ? in that order.
(g) Authors must be consistent in the style of their figures. This includes, but is not restricted to, the use of symbols and lettering size, type, style and positioning on the figures.
3. Reference format
(a) In the text, references should be quoted as the name of the first author and year in chronological order. Multiple authors are indicated by "et al.", except when there are only two authors, in which case both names are written. For example,
The pattern of the pathology instead represents a synaptically connected network of neurons (Braak and Braak, 1991; Morris, 1997). This hypothesis was recently proposed by Nagy et al. (1997)...
(b) The reference list should be typed on a separate sheet(s) of paper at the end of the manuscript, in alphabetical order and arranged as follows: authors' names and initials, year, title of the article, abbreviated title of the journal, volume, first and last page numbers. Journal titles should be abbreviated according to the rules adopted in the fourth edition of the World List of Scientific Periodicals (Butterworths, 1965). Note that first and last pages are given in full. For example, Keverne EB, Levy F, Guevara-Guzman R, Kendrick KM, 1993. Incluence of birth and maternal experience on olfactory bulb neurotransmitter release. Neuroscience 56: 557-565.
(c) References to books should include the authors' names and initials, year, title of book, volume, publisher, place of publication and page numbers. Where relevant, the title of a paper within a book, and the editor's name(s) should be given. For example, Morris, J. H., 1997. Alzheimer's disease. In: Esiri, M. M., Morris, J. H. (Eds.), The Neuropathology of Dementia, vol. 2. Cambridge University Press, Cambridge, pp. 70-121.
4. Presentation of data in tables or figures
(a) Care should be taken to present data in a precise manner. For example, in the interests of accuracy and space simple bargraphs should not be used when the data can be equally well given numerically in a table or the main text, and should only be used in figures when there are 10 or more data points. Those bargraphs demonstrating an increasing time-base on the x-axis, dose-response, and autocorrelograms or similar are acceptable. Authors should avoid applying unnecessary styling to bargraphs. The Editorial Office reserves the right to request the conversion of bargraphs to tables or text.
(b) It is the policy of Neuroscience to publish high-quality half-tone (black and white or colour plates) and line art illustrations. Authors must submit high-quality original figures both for publication and for review (except for a Letter to Neuroscience). Xerox copies of figures are not acceptable for referees. Original illustrations for publication must be submitted as hard copy and, in addition (where possible), as digital files. Colour plates or line drawings will be charged to the authors. The exact cost will be given on request.
(c) Hard copy figures
(i) Each figure must have its number, the first author's name and Neuroscience written outside of the image area on its back.
(ii) Line drawings should be high-quality prints (photographic or laser prints) or drawn on white card and submitted in a form suitable for direct reproduction.
(iii) Symbols on graphs, etc. should be inserted by the author using the following standard characters: ?
- ,
 ,  , □,  , X, +
1 (iv) Half-tones must be supplied as high-quality glossy prints or original mounted half-tones (such as micrographs) and arranged as they are to appear in the Journal. Where possible a digital version of each half-tone should be supplied. The maximum area available is 167 x 245 mm. Half-tones must be arranged to make use of as much of this space as possible, although allowance for figure legends may be made wherever possible. Any labelling should not occur within 10 mm of the edges of the half-tones. Authors must clearly describe in the legend all manipulations made to digital data that were collected as images, and images which have been scanned and printed for publication. This should include, but is not limited to, stating minor manipulations such as digitally sharpening an image, adjusting the contrast and/or brightness, or the application of any filters or algorithms to the image. At any time, the Chief and Associate Editor reserve the right to request that an author supply an unaltered/ unedited original of any manipulated image in order to compare with the submitted figure.
(v) Photographs should be labelled by the authors with high-quality commercial lettering; they should be prepared mounted on card exactly (same size) as they will appear in the Journal.
(vi) Original figures will be destroyed by the Publisher three months after an issue is published unless the authors request their return in writing at the time they submit the paper.
(d) Electronic figures. The digital version of each figure should be clearly named and identically match the hard copy version. Authors will be required to submit final revised versions of manuscripts and figures in digital format and on separate disks, with details of the operating system and software employed. Please refer to the Elsevier Science guide to the submission of artwork web page http://authors.elsevier.com for guidance on what file types are acceptable by the publisher.
Corrections to the proof should be restricted to printer's errors. Substantial alterations may be charged to the author. Return of corrected proofs should be done within 48 hours of receipt. The return of proofs is taken to indicate that all the authors are satisfied with the format and contents of the paper. Requests from authors for corrections to be made following publication will not be accepted if the mistake was apparent and could have been changed at the proof stage, or if the request comes more than two months following publication of the paper.
Reprints of each paper can be obtained at a reasonable cost by ordering on the reprint order form supplied with the proofs.
Rejected manuscripts. To save on postage costs, only the original copy of each rejected manuscript will be returned to the authors; the remaining copies will be destroyed.
IV. PAPER SUBMISSION CHECKLIST
(Please complete and send with all manuscripts.)
Title:
First Author:
Corresponding Author:
Section Editor:
Please complete the following:
 The original and four copies of manuscript and figure are enclosed
An electronic copy of the manuscript and figures are enclosed on separate disks
An electronic file of cover letter, title page, abstract and references is enclosed
List of suitable referees enclosed with e-mail and postal address (4 minimum)
Please ensure your paper complies with the following:
Manuscript is double-spaced
Format: title page, Abbreviations, Running title, Abstract and Keywords, Introduction, Experimental Procedures, Results, Discussion, References, Table and Figure Legends
Initials are used rather than first names for authors on title page
Full contact details of corresponding author included (address, telephone, fax and e-mail)
All abbreviations used in main text are listed and in alphabetical order
The running title is less than 56 character spaces long
The title and abstract contain minimal abbreviations, and all are defined
The final paragraph of the abstract clearly states the implications of the work in non-specialist terms
There are a maximum of 6 (six) Keywords, which are not words already in the title
There are no results presented in the introduction
All relevant statistical data is presented
Each figure has, on a separate page, (i) a caption and (ii) a legend
There are no simple bar graphs in the stand alone figures with less than 10 data points
Editorial Board
Chief Editor:
D.G. Amaral, Department of Psychiatry TB 171, University of California, Davis, One Shields Avenue, Davis, CA 95616, USA Tel: 001 530 754 7020, Email: David G. Amaral [NeuroscienceEditor@ucdavis.edu]
Associate Editor:
O.P. Ottersen, Centre for Molecular Biology and Neuroscience, Institute of Basic Medical Sciences, Department of Anatomy, Sognsvannsv. 9, P O Box 1105, Blindern, NO-0317 Oslo, Norway Email: editor.neuroscience@basalmed.uio.no
Section Editor Behavioral Neuroscience
E. Moser, Center for the Biology of Memory, MTFS, Neuroscience Unit, Norwegian University of Science and Technology, NO 7489, Trondheim, Norway Email: edvard.moser@cbm.ntnu.no
Section Editor Cellular Neuroscience
C. Sotelo, INSERM U-106, Batiment de Pediatrie, Hopital de la Salpetriere, 47 Bd de l'Hopital, 75651 Paris Cedex 13, France. Fax: 00 33 1 45 70 99 90, Email: Sotelo@chups.jussieu.fr
S.J. Redman, Division of Neuroscience, Australian National University, John Curtin School of Medical Research, Canberra, ACT, Australia Tel: 61 62 492 602, Fax: 61 62 492 687, Email: steve.redman@anu.edu.au
Section Editor Clinical Neuroscience
D.A. Lewis, Department of Psychiatry, University of Pittsburgh, W1652BST, 3811 O'Hara Street, Pittsburgh, PA 15213-2593, USA. Tel: 001 412 624 3934, Fax: 001 412 624 9910, Email: lewisda@msx.upmc.edu
Section Editor Cognitive Neuroscience
R.J. Dolan, Wellcome Department of Cognitive Neurology, Queen Square, London, WC1N 3BG, UK. Tel: +44 0171 833 7472, Fax: +44 0171 813 1420, Email: Rdolan@fil.ion.ucl.ac.uk
Section Editor Developmental Neuroscience
J.L.R. Rubenstein, LPPI Box F-0984, University of California-San Francisco, 401 Parnassus Avenue, San Francisco, CA 94143-0984, USA. Tel: 001 415 476 7862, Fax: 001 415 476 7884, Email: jlrr@cgl.ucsf.edu
Section Editor Molecular Neuroscience
W. Sieghart, Brain Research Institute, University of Vienna, Division of Biochemistry and Molecular Biology, Spitalgasse 4, A-1090 Vienna, Austria; Tel: 0043 1 4277 62950, Fax: 0043 1 4277 62959, Email: Werner.Sieghart@univie.ac.at
Section Editor Neuropharmacology
J.P. Bolam, MRC Anatomical and Neuropharmacology Unit, Mansfield Road, Oxford OX1 3TH, UK. Tel: +44 1865 271869, Fax: +44 1865 271647, Email: Paul.Bolam@pharm.ox.ac.uk
Section Editor Systems Neuroscience
G. Buzsaki, Center for Molecular and Behavioural Neuroscience, Rutgers University, 197 University Avenue, Newark, NJ 07102, USA. Fax: 001 201 648 1272, Email: buzsaki@axon.rutgers.edu
K. Tanaka, Cognitive Brain Mapping Laboratory, RIKEN Brain Science Institute, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan. Fax: +81 (48) 462-4651, Email: keiji@postman.riken.go.jp
Section Editor Sensory Systems
D. Fitzpatrick, Department of Neurobioligy, Duke University, 427c Bryan Research Building, Box 3209 Medical Center, Durham, NC 27710, USA Tel: 001 919 684 5385, Fax: 001 919 684 4431, Email: fitzpat@neuro.duke.edu
Section Editor Special Issues and Commentaries
J.H. Morrison, Mt Sinai School of Medicine, Box 1639, One Gustave Levy Place, New York, NY 10029 6574, USA Tel: 001 212 241 1752, Fax: 001 212 849 2510
Reviewing Editors
E. Abercrombie, Newark, NJ, USA
A.A. Alonso, Montreal, Canada
T. Arendt, Leipzig, Germany
W.W. Blessing, SA, Australia
T.V.P. Bliss, London, UK
P. Brundin, Lund, Sweden
E. Cattaneo, Milan, Italy
J.T. Coyle, Belmont, MA, USA
A.C. Cuello, Montreal, Canada
L. Della Corte, Firenze, Italy
F.E. Dudek, Fort Collins, CO, USA
D. Edgar, Liverpool, UK
M.M. Esiri, Oxford, UK
U.T. Eysel, Bochum, Germany
R.L.M. Faull, Auckland, New Zealand
Y. Fregnac, Gif-sur-Yvette, France
T.F. Freund, Budapest, Hungary
M. Frotscher, Freiburg, Germany
F.H. Gage, La Jolla, CA, USA
C.M. Gall, Irvine, CA, USA
J. Garthwaite, London, UK
C.R. Gerfen, Bethesda, MD, USA
S.G.N. Grant, Edinburgh, UK
J.A. Gray, London, UK
H.J. Groenewegen, Amsterdam, The Netherlands
R.W. Guillery, Madison, WI, USA
M. Hamon, Paris, France
P.J. Harrison, Oxford, UK
Z. Henderson, Leeds, UK
J. Herbert, Cambridge, UK
M. Herkenham, Bethesda, MD, USA
P.R. Hof, New York, NY, USA
T. Hökfelt, Stockholm, Sweden
R. Insausti, Albacete, Spain
B.E. Jones, Montreal, Canada
E.G. Jones, Davis, CA, USA
G. Ju, Xi'an, PRC
B.I. Khodorov, Moscow, Russia
T. Kosaka, Fukuoka, Japan
O.A. Krishtal, Kiev, Ukraine
S.N. Lawson, Bristol, UK
U.L. Lendahl, Stockholm, Sweden
J.D. Levine, San Francisco, CA, USA
C.A. Marsden, Nottingham, UK
A. Martin, Bethesda, MD, USA
A.I. Matus, Basle, Switzerland
?Mugnaini, Chicago, IL, USA
D.G. Nicholls, Novato, CA, USA
T. Ono, Toyama, Japan
O. Paulsen, Oxford, UK
V.H. Perry, Southampton, UK
A. Pitkanen, Kuopio, Finland
J.M. Polak, London, UK
R. Quirion, Verdun, Canada
H.A. Roberston, Halifax, NS, Canada
F. Rossi, Torino, Italy
R. A. Rush, Adelaide, Australia
T.E. Salt, London, UK
R. Schmidt-Kastner, Miami, FL, USA
M. Segal, Rehovot, Israel
R. Shigemoto, Aichi, Japan
Y. Smith, Atlanta, GA, USA
S. Snyder, Baltimore, MD, USA
M.V. Sofroniew, Los Angeles, CA, USA
P. Somogyi, Oxford, UK
K. Starke, Freiburg, Germany
M. Steriade, Qu¨¦bec, Canada
T.C. Sudhof, Dallas, TX, USA
J.M. Tepper, Newark, NJ, USA
D.T. Theodosis, Bordeaux, France
A.M. Thomson, London, UK
A. Todd, Glasgow, UK
K. Unsicker, Heidelberg, Germany
S.R. Vincent, Vancouver, Canada
L. Vyklicky, Prague, Czech Republic
X.S.T. Wan, Beijing, PRC
W. Wisden, Heidelberg, Germany
M.P. Witter, Amsterdam, The Netherlands
Y. Yarom, Jerusalem, Israel
D.S. Zahm, St Louis, MO, USA
R.E. Zigmond, Cleveland, OH, USA
Founding Editors:
P.G. Kostyuk
R. Llin¨¢s
A.D. Smith
|
